FDA Boxed Warning for Botulinum Toxin Products

被引：0

|

作者：

不详

机构：

来源：

JOURNAL OF DRUGS IN DERMATOLOGY | 2009年 / 8卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

收藏

页码：595 / 596

页数：2

相关论文

共 50 条

[41] US FDA reviewing safety of botulinum toxin type A and B
Reactions Weekly, 2008, 1189 (1) : 2 - 2
[42] National antidepressant prescribing in children and adolescents with mental health disorders after an FDA boxed warning
Mittal, Manish
Harrison, Donald L.
Miller, Michael J.
Brahm, Nancy C.
RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2014, 10 (05): : 781 - 790
[43] PHARMACOEPIDEMIOLOGY AND THE IMPACT OF THE BOXED WARNING
Bridge, Jeff
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2020, 59 (10): : S114 - S114
[44] New boxed warning for Tygacil
Reactions Weekly, 2013, 1472 (1) : 3 - 3
[45] New boxed warning for leflunomide
Reactions Weekly, 2010, 1311 (1) : 6 - 6
[46] Boxed warning for lamotrigine in US
Reactions Weekly, 1997, 647 (1) : 2 - 2
[47] Botulinum toxin products: name changes for safety
Reactions Weekly, 2009, 1264 (1) : 2 - 2
[48] Boxed warning added to `Cafergot'
Reactions Weekly, 2002, 929 (1) : 2 - 2
[49] FDA warning companies not to sell unapproved cannabidiol products
Reactions Weekly, 2021, 1850 (1) : 5 - 5
[50] Trends in utilization of smoking cessation agents before and after the passage of FDA boxed warning in the United States
Shah, Drishti
Shah, Anuj
Tan, Xi
Sambamoorthi, Usha
DRUG AND ALCOHOL DEPENDENCE, 2017, 177 : 187 - 193

← 1 2 3 4 5 →